September 24, 2021. Remdesivir May Reduce Mortality and Hospitalizations in Patients with COVID-19
This press release shows a phase 3, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of remdesivir in the outpatient setting. .
This study, showed a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by day 28 compared with placebo (0.7% versus 5.3%). It is to note that no deaths occurred in either group.
This study shows that the best use of remdesivir may be to reduce hospitalization due to COVID-19. In order to see a mortality benefit a much larger study is needed.